

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**SCHEDULE 13D**  
Under the Securities Exchange Act of 1934  
(Amendment No. 1)\*

**Outlook Therapeutics, Inc.**  
(Name of Issuer)

**Common Stock, par value \$0.01 per share**  
(Title of Class of Securities)

**69012T 206**  
(CUSIP Number)

**Syntone Ventures LLC**  
**1517 Champlain Crest Way**  
**Cary, NC 27513**  
**Attn: President Telephone: (781) 308-**  
**0823**

(Name, Address and Telephone Number of Person Authorized  
to Receive Notices and Communications)

**February 3, 2021**  
(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

---

1.	NAMES OF REPORTING PERSONS <b>Syntone Ventures LLC</b>	
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3.	SEC USE ONLY	
4.	SOURCE OF FUNDS <b>AF</b>	
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) <input type="checkbox"/>	
6.	CITIZENSHIP OR PLACE OF ORGANIZATION <b>Delaware</b>	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	7.	SOLE VOTING POWER <b>0</b>
	8.	SHARED VOTING POWER <b>19,823,045</b>
	9.	SOLE DISPOSITIVE POWER <b>0</b>
	10.	SHARED DISPOSITIVE POWER <b>19,823,045</b>
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON <b>19,823,045</b>	
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES <input type="checkbox"/>	
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) <b>11.7%</b>	
14.	TYPE OF REPORTING PERSON <b>OO</b>	

- (1) This percentage is calculated based upon 168,776,876 Shares outstanding based on (i) 127,183,109 outstanding shares of common stock reported by Outlook Therapeutics, Inc., a Delaware corporation (the "Issuer") in its Annual Report on Form 10-K for the year ended September 30, 2020, plus (ii) 38,593,767 shares issued in the February 2021 underwritten public offering and (iii) 3,000,000 shares issued to the concurrent placement to the reporting persons. As used in this Schedule 13D, as amended, "shares" means shares of common stock, par value \$0.01 per share (the "Shares"), of the Issuer.

1.	NAMES OF REPORTING PERSONS <b>Syntone LLC</b>	
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3.	SEC USE ONLY	
4.	SOURCE OF FUNDS <b>AF</b>	
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) <input type="checkbox"/>	
6.	CITIZENSHIP OR PLACE OF ORGANIZATION <b>Delaware</b>	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	7.	SOLE VOTING POWER <b>0</b>
	8.	SHARED VOTING POWER <b>19,823,045</b>
	9.	SOLE DISPOSITIVE POWER <b>0</b>
	10.	SHARED DISPOSITIVE POWER <b>19,823,045</b>
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON <b>19,823,045</b>	
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES <input type="checkbox"/>	
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) <b>11.7%</b>	
14.	TYPE OF REPORTING PERSON <b>OO</b>	

- (1) This percentage is calculated based upon 168,776,876 Shares outstanding based on (i) 127,183,109 outstanding shares of common stock reported by the Issuer in its Annual Report on Form 10-K for the year ended September 30, 2020, plus (ii) 38,593,767 shares issued in the February 2021 underwritten public offering and (iii) 3,000,000 shares issued to the concurrent placement to the reporting persons.

1.	NAMES OF REPORTING PERSONS <b>Syntone Technologies Group Co., Ltd.</b>	
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3.	SEC USE ONLY	
4.	SOURCE OF FUNDS <b>WC</b>	
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) <input type="checkbox"/>	
6.	CITIZENSHIP OR PLACE OF ORGANIZATION <b>China</b>	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	7.	SOLE VOTING POWER <b>0</b>
	8.	SHARED VOTING POWER <b>19,823,045</b>
	9.	SOLE DISPOSITIVE POWER <b>0</b>
	10.	SHARED DISPOSITIVE POWER <b>19,823,045</b>
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON <b>19,823,045</b>	
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES <input type="checkbox"/>	
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) <b>11.7%</b>	
14.	TYPE OF REPORTING PERSON <b>CO</b>	

- (1) This percentage is calculated based upon 168,776,876 Shares outstanding based on (i) 127,183,109 outstanding shares of common stock reported by the Issuer in its Annual Report on Form 10-K for the year ended September 30, 2020, plus (ii) 38,593,767 shares issued in the February 2021 underwritten public offering and (iii) 3,000,000 shares issued to the concurrent placement to the reporting persons.

This Amendment No. 1 to Schedule 13D (this "Amendment") amends and supplements the Schedule 13D previously filed on June 12, 2020 (the "Initial Statement"), by the Reporting Persons (as defined below) relating to common stock, par value \$0.01 per share (the "Shares"), of Outlook Therapeutics, Inc., a Delaware corporation (the "Issuer").

This Amendment is being filed as a result of the February 3, 2021 acquisition of 3,000,000 Shares by the Reporting Persons pursuant to that certain securities purchase agreement dated January 28, 2021, and to also report the July 2020 purchase of 823,045 Shares by the Reporting Persons pursuant to that certain securities purchase agreement dated June 22, 2020.

Unless otherwise indicated herein, capitalized terms used but not defined in this Amendment shall have the same meaning ascribed to such terms in the Initial Statement. Except as set forth herein, this Amendment does not modify any information previously reported by the Reporting Persons in the Initial Statement.

As used in this Amendment, Reporting Persons means (i) Syntone Ventures LLC, a Delaware limited liability company ("Syntone"), (ii) Syntone LLC, a Delaware limited liability company (the "Manager"), and (iii) Syntone Technologies Group Co. Ltd. ("Syntone Technologies"), a company organized in the People's Republic of China ("PRC").

### **Item 3. Source and Amount of Funds or Other Consideration**

Item 3 is hereby amended to add disclosure as follows:

On June 22, 2020, the Issuer entered into a Securities Purchase Agreement (the "June Purchase Agreement") with Syntone, pursuant to which the Issuer agreed to sell and issue, in a private placement, an aggregate of 823,045 Shares at a purchase price of \$1.215 per share, for aggregate gross proceeds to the Issuer of approximately \$1.0 million, which closed on July 15, 2020. The source of funds for such purchase was a capital contribution made to Syntone by the Manager, the source of funds of which were from the working capital of Syntone Technology.

On January 21, 2021, the Issuer entered into a Securities Purchase Agreement (the "January Purchase Agreement") with Syntone, pursuant to which the Issuer agreed to sell and issue, in a private placement, an aggregate of 3,000,000 Shares at a purchase price of \$1.00 per share, for aggregate gross proceeds to the Issuer of \$3.0 million, which closed on February 3, 2021. The source of funds for such purchase was a capital contribution made to Syntone by the Manager, the source of funds of which were from the working capital of Syntone Technology.

As a result of the transactions described in this Item 3, the Reporting Persons may each be deemed to be the beneficial owner of approximately 11.7% of the outstanding Shares.

### **Item 5. Interest in Securities of the Issuer**

Item 5 is amended to add disclosure as follows:

(a)–(b) As of the date of this filing, Syntone Ventures owns a total of 19,823,045 Shares. Based upon (i) 127,183,109 outstanding Shares reported by the Issuer in its Annual Report on Form 10-K for the year ended September 30, 2020, plus (ii) 38,593,767 Shares issued in the February 2021 underwritten public offering and (iii) 3,000,000 Shares issued to the concurrent placement to the Reporting Persons, this represents approximately 11.7% of the issued and outstanding Shares pursuant to Rule 13d-3 under the Securities Act.

- (c) No transactions in the Shares were effected during the past 60 days by the Reporting Persons.
  - (d) Not applicable.
  - (e) Not applicable.
-

Item 7 is hereby amended to amend Exhibit1 and add Exhibits 4 and 5 as follows

**Item 7. Material to be Filed as Exhibits**

Exhibit	Description
1.	Joint Filing Agreement among Syntone Ventures LLC, Syntone LLC and Syntone Technologies Co., Ltd., dated as of February 4, 2021.
4.	Securities Purchase Agreement, dated June 22, 2020, by and between the Issuer and Syntone (incorporated by reference to Exhibit 10.2 to the Issuer's Form 8-K (SEC File No. 001-37759), filed with the SEC on June 23, 2020).
5.	Securities Purchase Agreement, dated January 28, 2021, by and between the Issuer and Syntone (incorporated by reference to Exhibit 10.1 to the Issuer's Form 8-K (SEC File No. 001-37759), filed with the SEC on February 2, 2021).

---

**SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 4, 2021.

**SYNTONE VENTURES LLC**

By: /s/ Jiahui Zheng

Name: Jiahui Zheng

Title: Attorney-in-Fact

**SYNTONE LLC**

By: /s/ Jiahui Zheng

Name: Jiahui Zheng

Title: Attorney-in-Fact

**SYNTONE TECHNOLOGIES CO., LTD.**

By: /s/ Jiahui Zheng

Name: Jiahui Zheng

Title: Attorney-in-Fact

---

**JOINT FILING AGREEMENT**

The undersigned hereby agree that this Amendment No. 1 to the Statement on Schedule 13D, dated February 4, 2021 (the "Schedule 13D/A"), with respect to the common stock, par value \$0.01 per share, of Outlook Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Joint Filing Agreement (this "Agreement") shall be included as an Exhibit to the Schedule 13D. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 4th day of February, 2021.

**SYNTONE VENTURES LLC**

By: /s/ Jiahui Zheng

Name: Jiahui Zheng

Title: Attorney-in-Fact

**SYNTONE LLC**

By: /s/ Jiahui Zheng

Name: Jiahui Zheng

Title: Attorney-in-Fact

**SYNTONE TECHNOLOGIES CO., LTD.**

By: /s/ Jiahui Zheng

Name: Jiahui Zheng

Title: Attorney-in-Fact

---